Asensus Surgical

Asensus Surgical, Inc. is a medical device company, which digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. It enables the use of advanced capabilities like augmented intelligence, connectivity and robotics in laparoscopy, and addresses the current clinical, cognitive, and economic shortcomings in surgery. The Senhance Surgical System features a machine vision system for use in robotic surgery, which is powered by the new Intelligent Surgical Unit (ISU) that enables augmented intelligence in surgery and brings the benefits of digital laparoscopy to patients around the world while staying true to the principles of value-based healthcare. The company was founded by William N. Starling on August 19, 1988 and is headquartered in Durham, NC.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Asensus Surgical reports Q1 loss but eyes stability through acquisition

Asensus Surgical's Q1 2024 performance showed a significant net loss, but the potential acquisition by KARL STORZ offers financial stability. The company aims to sustain operations into Q3 2024 and beyond with available cash and additional financing. Ongoing initiatives focus on advancing surgical systems and expanding global programs.

Asensus Surgical reports Q2 losses, merger vote adjourned

Asensus Surgical faces financial struggles with a significant net loss and liquidity concerns.
The proposed merger with Karl Storz offers a potential strategic advantage but hinges on stockholder approval.
Addressing operational inefficiencies and investor engagement are critical for long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Asensus Surgical is a digital interface between the surgeon and patient to improve minimally invasive surgery through digital laparoscopy. They enable capabilities such as augmented intelligence, connectivity, and robotics in laparoscopy and seek to address the current clinical, cognitive, and economic shortcomings in surgery.

RESEARCH TRIANGLE PARK, N.C., April 03, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical , Inc. (NYSE American: ASXC) (“Asensus” or the “Company”), a medical device company that is digitizing the interface between the surgeon and the patient, today announced that it has entered into a non-binding letter of intent (the “letter of intent”) with KARL STORZ SE & Co. KG, an independent, family-owned global medical technology company (“KARL STORZ”) to engage in diligence and negotiations regarding the terms of a potential transaction whereby KARL STORZ may acquire Asensus.

Asensus Surgical, Inc. Announces Non-Binding Acquisition Proposal and Exclusivity Arrangement with KARL STORZ SE & Co. KG

Asensus Surgical, Inc. (ASXC) Q4 2023 Earnings Call Transcript

RESEARCH TRIANGLE PARK, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical , Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced its operating and financial results for the fourth quarter and full year 2023.

Asensus Surgical, Inc. Reports Operating and Financial Results for the Fourth Quarter 2023 and Full Year 2023

RESEARCH TRIANGLE PARK, N.C., March 15, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical , Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced today that it plans to release fourth quarter and full year 2023 financial and operating results after the market closes on Thursday, March 21, 2024. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently webcast.

Asensus Surgical, Inc. Schedules Fourth Quarter and Full Year 2023 Financial and Operating Results Conference Call for March 21, 2024

RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC) announced today that Shameze Rampertab, Executive Vice President and Chief Financial Officer, will participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference. The Company's virtual presentation will take place on Tuesday, March 12, 2024 at 4:40 pm Eastern Time.

Asensus Surgical to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference

RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced the completion of more than 1,000 successful cases each at three hospitals utilizing the Senhance® Surgical System: Klaipeda University Hospital (Lithuania), Presidential Clinic Astana (Kazakhstan), and Evangelisches Krankenhaus Wesel GmbH (Germany).

Asensus Surgical Celebrates 1,000 Senhance Cases Completed at Three Global Hospitals

Asensus Surgical (ASXC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -25.24% in 4 Weeks, Here's Why Asensus Surgical (ASXC) Looks Ripe for a Turnaround

Editas Medicine

Hologic

Illumina

Johnson & Johnson

Moderna

Verve Therapeutics

With so many question marks facing the viability of the equities sector, concerned investors may want to turn their attention to compelling healthcare stocks. Primarily, the sector benefits from permanent relevance.

7 Mighty Healthcare Stocks Changing the Game of Medicine

The Fourth Hospital to Initiate a Senhance® Surgical System Dedicated to Pediatric Procedures The Fourth Hospital to Initiate a Senhance® Surgical System Dedicated to Pediatric Procedures

Asensus Surgical Announces Nagoya University Hospital in Japan to Initiate Senhance Surgery Program

Asensus Surgical's (ASXC) latest Surgeon Lab helps it move closer to a finalized LUNA product.

Asensus Surgical (ASXC) Completes Surgeon Lab for LUNA

RESEARCH TRIANGLE PARK, N.C., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient, provided a preliminary 2023 year-end corporate update.

Asensus Surgical Provides Preliminary 2023 Year-End Corporate Update

Canaan Inc.

Leidos Hld

Microsoft

D-Wave Quantum Inc

With Nvidia (NASDAQ: NVDA ) skyrocketing to blistering heights in 2023, the question on everyone's mind now is as follows: what will be the hottest tech stocks in 2024? At the start of the new year, it's worth carefully examining this inquiry.

The 7 Hottest Tech Stocks to Watch in 2024

RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced a key development milestone for LUNA™, the Company's second-generation surgical robotic system.

Asensus Surgical Completes In Vivo Surgeon Lab for LUNA Surgical Robotic System

RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient, announced that the management team will participate and present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 3:00pm EST (12:00 PM PST).

Asensus Surgical, Inc. to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Senhance® System to be placed at a pediatric hospital in Timisoara, Romania Senhance® System to be placed at a pediatric hospital in Timisoara, Romania

Asensus Announces Sale of Senhance Robotic System in Romania

Globus Medical

Microbot Medical

Every now and then, speculation – within carefully defined limits – may be appropriate, which brings us to the case for medical robotics stocks to buy. Sure, you can gamble on just about anything these days and a non-zero probability exists for their upside.

3 Stocks at the Forefront of Medical Robotics

Senhance® System to be placed at a hospital in the Commonwealth of Independent States Senhance® System to be placed at a hospital in the Commonwealth of Independent States

Senhance Robotic System Sold by Asensus Surgical

Asensus Surgical, Inc. (NYSE:ASXC ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Mark Klausner - Westwicke Partners Anthony Fernando - President and CEO Shameze Rampertab - CFO Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Ross Osborn - Cantor Fitzgerald Operator Good afternoon and welcome to the Asensus Surgical Inc. Third Quarter Financial and Operating Result Conference Call.

Asensus Surgical, Inc. (ASXC) Q3 2023 Earnings Call Transcript

RESEARCH TRIANGLE PARK, N.C., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical , Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced its operating and financial results for the third quarter 2023.

Asensus Surgical, Inc. Reports Operating and Financial Results for the Third Quarter 2023

Senhance® System to be placed at a pediatric hospital in the Commonwealth of Independent States Senhance® System to be placed at a pediatric hospital in the Commonwealth of Independent States

Asensus Surgical Announces Sale of Senhance Robotic System

RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced an agreement with diversified manufacturer Flex (NASDAQ: FLEX) for design and advanced manufacturing services for Asensus's previously-announced LUNA Surgical System, a next-generation surgical robot platform.

Asensus Surgical, Inc. Announces Agreement with Flex for Design and Advanced Manufacturing Services for the LUNA™ Surgical System

RESEARCH TRIANGLE PARK, N.C., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical , Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient announced today that it plans to release 2023 third quarter financial and operating results after the market closes on Tuesday, November 14, 2023. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently webcast.

Asensus Surgical, Inc. Schedules Third Quarter Financial and Operating Results Conference Call for November 14, 2023

RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced that Klinikum Idar-Oberstein Hospital located in Germany, has entered into a lease agreement to utilize a Senhance® Surgical System.

Asensus Surgical Announces Klinikum Idar-Oberstein Hospital in Germany to Initiate Senhance Surgery Program

Aurora Cannabis

Better Home & Finance Holding Co

Inpixon

Nektar Therapeutics

Nemaura Medical

Novo Integrated Sciences, Inc.

Founder SPAC

Senseonics Holdings

Synaptogenix

Let's be honest – penny stocks priced at less than a buck hold an irresistible appeal. Even a small investment could potentially lead to insane returns.

Best Penny Stocks To Buy Now? 10 Under $1 To Watch

Penny stocks priced under $1 per share have attracted a dedicated following among traders seeking massive returns. While penny stocks are inherently high-risk investments, the potential reward with these low-priced shares is exponentially higher compared to traditional blue chip stocks.

News for Asensus Surgical Stock (ASXC)